Harnessing Multikinase Inhibitors to Weaponize the Next Generation Against Multiple Cancer Indications

Time: 2:30 pm
day: Day One


  • Discussing the potential to treat multiple cancer indications by targeting multiple MOAs with multi-kinases
  • Introducing narazaciclib (ON123300) – discussing its unique MOA, targeting properties and safety profile through preclinical studies
  • Outlining phase 1 study results to date and the future clinical development pathway of narazacliclib